AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30779339
Drug: Tezepelumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (AMG 157) 210 mg every 28 days
Trial: 30779339
Drug: Tezepelumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (AMG 157) 210 mg every 14 days
Trial: 30779339
Drug: Tezepelumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (AMG 157) 210 mg every 7 days
Trial: 26156560
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (phylloquinone) 10 mg/day for 8 weeks
Trial: 12417283
Drug: apo A‐I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apo A‐I <1.2 g/l
Trial: 12417283
Drug: apo B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apo B > or =1.4 g/l
Trial: 2200382
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg every 12 hours)
Trial: 2200382
Drug: Verapamil sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil sustained release (240 mg/d)
Trial: 31563659
Drug: Awake sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awake sedation with target controlled propofol infusion
Trial: 30472337
Drug: 0.075% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% capsaicin lotion
Trial: 23371961
Drug: Steroid-sensitive nephrotic
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-sensitive nephrotic syndrome
Trial: 7805356
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (1500 mg)
Trial: 7805356
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (800 or 1000 mg)
Trial: 7805356
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (400 or 500 mg)
Trial: 7805356
Drug: Comparators (spectinomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparators (spectinomycin, thiamphenicol, ampicillin, or amoxicillin plus probenecid)
Trial: 23850318
Drug: Personalized antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antiplatelet therapy according to CYP2C19 phenotype
Trial: 23850318
Drug: Conventional antiplatelet
RxNorm normalized name: magaldrate and antiflatulents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antiplatelet treatment
Trial: 21596876
Drug: Remifentanil 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.2 μg/kg/min (group HI)
Trial: 21596876
Drug: Remifentanil 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.05 μg/kg/min (group LO)
Trial: 21596876
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 30 mg/kg at induction followed by 10 mg/kg/h (group HM)
Trial: 9359709
Drug: Recombinant herpes
RxNorm normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant herpes simplex virus type 2 glycoproteins D and B vaccine in MF59 adjuvant
Trial: 8269444
Drug: Low-dose bisoprolol/HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose bisoprolol/HCTZ 6.25 mg
Trial: 8269444
Drug: Monotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy and placebo
Trial: 3946169
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone (30 mg/kg)
Trial: 30461306
Drug: Avelumab in
RxNorm normalized name: avelumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab in combination with chemoradiotherapy (CRT)
Trial: 30461306
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with chemoradiotherapy (CRT)
Trial: 28213776
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion (TCI) sedation endoscopy (TCI-DISE)
Trial: 28213776
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion (TCI-DISE)
Trial: 22092126
Drug: Fentanyl 0
RxNorm normalized name: fentanyl 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0 mcg/kg (F0)
Trial: 22092126
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 mcg/kg (F1)
Trial: 22092126
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 mcg/kg (F1.5)
Trial: 22092126
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mcg/kg (F2)
Trial: 17035445
Drug: Intranasal trivalent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal trivalent, live attenuated, cold‐adapted influenza virus vaccine (TC)
Trial: 17035445
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (TP)
Trial: 15167171
Drug: Enoxaparin or
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin or unfractionated heparin (control)
Trial: 8213578
Drug: Enalapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (1 mg infusion followed by oral treatment to a target dose of 20 mg/day)
Trial: 3315271
Drug: BID (twice-daily,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID (twice-daily, equally divided 12 hr)
Trial: 3315271
Drug: OD-PM (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD-PM (once-daily evening)
Trial: 3315271
Drug: OD-AM (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD-AM (once-daily morning)
Trial: 25175480
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate combination inhaler (SFC)
Trial: 25175480
Drug: No FP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No FP dose change
Trial: 25175480
Drug: Increased FP
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased FP dose
Trial: 18724209
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ITB treatment)
Trial: 15910297
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) administered at a daily oral dose of 2 x 1000 mg for the first 6 postoperative months, tapered within 2 weeks thereafter.
Trial: 15910297
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received fluocortolon and topical prednisolone acetate, no specific intervention mentioned.
Trial: 11156812
Drug: Bupropion (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (up to 200 mg b.i.d.)
Trial: 9625292
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus nicotinamide (0.5 g, three tablets/day)
Trial: 9625292
Drug: Current sulphonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current sulphonylureas plus nicotinamide (0.5 g, three tablets/day)
Trial: 9625292
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus placebo (3 tablets/day)
Trial: 7836197
Drug: Dipyridamole (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.6 mg/kg)
Trial: 3282078
Drug: Interferon alfa-2B
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2B therapy for an additional 6 months (18 months total)
Trial: 3282078
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy after 12 months of interferon alfa-2B
Trial: 3282078
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with interferon alfa-2B after relapse
Trial: 3282078
Drug: Interferon alfa-2B
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2B therapy (standard dose of 2 X 10(6) U/m2 sc three times weekly)
Trial: 29409133
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg (anti-TNF-naive)
Trial: 29409133
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (anti-TNF-naive)
Trial: 29409133
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg (anti-TNF-IR)
Trial: 29409133
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (anti-TNF-IR)
Trial: 28013272
Drug: CSC-T (8-session,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSC-T (8-session, group-based comprehensive smoking cessation and trauma management treatment)
Trial: 21612744
Drug: Amikacin 125
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 125 ‐ 1,000 mg once‐daily or every‐other‐day
Trial: 17183433
Drug: Transfer after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer after initial treatment in local emergency room (group 2)
Trial: 17183433
Drug: Transfer after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer after initial treatment in local emergency room (group 3)
Trial: 15271158
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid warmer set at 38.5 degrees C on the dialysate and 1 L/hour of replacement fluid lines
Trial: 7898095
Drug: Systemic antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antihypertensive therapy
Trial: 28394459
Drug: Placebo (719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (719 mg maltodextrin)
Trial: 21700360
Drug: 5% minoxidil
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% minoxidil topical foam (MTF) once daily
Trial: 21700360
Drug: 2% minoxidil
RxNorm normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% minoxidil topical solution (MTS) twice daily
Trial: 7638994
Drug: Systemic narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic narcotic medications
Trial: 2507224
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding via needle catheter jejunostomy (NCJ) starting 12 hours postoperatively, advanced to 100-125 ml/h of full-strength diet
Trial: 782777
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride daily
Trial: 782777
Drug: Acidulated phosphate
RxNorm normalized name: Acidulated Phosphate Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidulated phosphate fluoride daily
Trial: 782777
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride weekly
Trial: 782777
Drug: Placebo weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo weekly
Trial: 23429913
Drug: GSK961081 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK961081 (400 μg once daily)
Trial: 23429913
Drug: GSK961081 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK961081 (200 μg twice daily)
Trial: 16877299
Drug: D-Ala1-peptide T-amide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Ala1-peptide T-amide (DAPTA) at a dose of 2 mg three times per day (tid)
Trial: 1356459
Drug: Fosfomycin 8
RxNorm normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin 8 g and metronidazole 1 g before operation and fosfomycin 8 g eight hours afterwards
Trial: 1356459
Drug: Doxycycline 400
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 400 mg and metronidazole 1 g before operation, and placebo eight hours afterwards
Trial: 29193234
Drug: Ropivacaine-dexmedetomidine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine-dexmedetomidine group (group RD, n = 19) received 15 mL of 0.5% ropivacaine with 100 μg (1 mL) dexmedetomidine
Trial: 25326169
Drug: Eptifibatide (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (0.2 mg/kg intra-arterial bolus)
Trial: 25326169
Drug: Heparin and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and/or aspirin (control group)
Trial: 17157651
Drug: Rescue medications
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medications and peak flow measurements
Trial: 12232545
Drug: Agomelatine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 5 mg
Trial: 12232545
Drug: Agomelatine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 100 mg
Trial: 11503260
Drug: Ceftibuten, 400
RxNorm normalized name: Ceftibuten, 400 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten, 400 mg once daily
Trial: 11503260
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics (b.i.d. dosing)
Trial: 11503260
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics (t.i.d. dosing)
Trial: 11503260
Drug: Dosing frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing frequency
Trial: 8184352
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment including specific manual treatment, such as manipulation and specific mobilization, muscle stretching, auto-traction, and cortisone injections
Trial: 8184352
Drug: Conventional activating
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional activating treatment
Trial: 26152416
Drug: Emodepside/Praziquantel Spot-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside/Praziquantel Spot-on (Profender®) - single application (3 mg/kg emodepside and 12 mg/kg praziquantel)
Trial: 21176949
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance (375 mg/m² every 8 weeks)
Trial: 18279829
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 2.0 mg/day for 2 weeks
Trial: 18279829
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 4.0 mg/day
Trial: 18279829
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 2.0 mg/day + medroxyprogesterone acetate
Trial: 18279829
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 microg
Trial: 12456499
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy with factor XIIIA Leu34 allele
Trial: 12456499
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy with factor XIIIB Arg95 allele
Trial: 8592524
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (100 mg per day) and subcutaneous erythropoietin (150 U per kilogram of body weight twice per week)
Trial: 8592524
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron and placebo
Trial: 1955630
Drug: Budesonide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (4 weeks treatment)
Trial: 1955630
Drug: Budesonide (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (one dose before exercise)
Trial: 28976863
Drug: Obinutuzumab-based chemotherapy
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-based chemotherapy
Trial: 28976863
Drug: Rituximab-based chemotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-based chemotherapy
Trial: 23829882
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (thrust or nonthrust manipulation) with a standardized exercise program for 2 treatment sessions
Trial: 23829882
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (thrust or nonthrust manipulation)
Trial: 18345342
Drug: Gastrocnemius stretching
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrocnemius stretching exercise (2 times daily for 3 weeks) with subtalar joint in supination or pronation
Trial: 12728166
Drug: Fluticasone aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone aqueous nasal spray (50 micro g) into each nostril twice daily
Trial: 8864314
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195 aerosol 2 mg
Trial: 8864314
Drug: BAY x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY x 7195 aerosol 4 mg
Trial: 6135830
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml HDCSV intradermally at each of eight sites
Trial: 6135830
Drug: Intramuscular (im)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (im) administration of HDCSV
Trial: 6135830
Drug: Adjuvanted vaccine
RxNorm normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccine given subcutaneously (sc)
Trial: 6135830
Drug: Semple vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semple vaccine
Trial: 3755650
Drug: piperazinedione at
RxNorm normalized name: 2,5-piperazinedione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperazinedione at a dose of 9 mg/m2 iv every 3 weeks
Trial: 24401928
Drug: NPLD (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPLD (50 mg/m² every 3 weeks for six cycles) + trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly) + paclitaxel (80 mg/m² weekly)
Trial: 24401928
Drug: Trastuzumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab + paclitaxel (same doses as above)
Trial: 14676103
Drug: Intravenous mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mesna regimen (20% ifosfamide dose) at 0, 4, and 8 h
Trial: 14676103
Drug: Intravenous/oral mesna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous/oral mesna regimen (i.v. mesna at 0 h, oral tablet at 2 and 6 h)
Trial: 2031511
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg q.i.d.)
Trial: 2031511
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg q.i.d.)
Trial: 2031511
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets q.i.d.)
Trial: 27454266
Drug: TP injections
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TP injections using particulate steroids mixed with a local anesthetic
Trial: 22328340
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (ADHD without MPH)
Trial: 16385874
Drug: CCR5 antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CCR5 antagonists (experimental medications)
Trial: 16385874
Drug: Enfuvirtide (previously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (previously approved medication)
Trial: 16385874
Drug: Other mechanisms
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other mechanisms of action (attachment inhibitors, CXCR4 inhibitors)
Trial: 2892336
Drug: SMS 201‐995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201‐995 plus injection sclerotherapy
Trial: 31431112
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin I assay with sex-specific thresholds (>16 ng/L women, >34 ng/L men)
Trial: 28390493
Drug: Cognitive‐behavioral conjoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral conjoint therapy (CBCT) for PTSD